NBIX Stock Recent News
NBIX LATEST HEADLINES
SAN DIEGO , Aug. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will participate at the Canaccord Genuity 45th Annual Growth Conference at 8:00 a.m. ET on Wednesday, August 13, 2025.
Neurocrine Biosciences' Ingrezza still generates most of its total revenues. This is their blockbuster drug. I also believe Ingrezza is well-positioned for future growth with new label additions, and IRA price protection warrants a bullish stance. Also, Crenessity's recent launch beat expectations, and the drug is key as a long-term second growth pillar.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants n - Corporate Participant Eiry Wyn Roberts - Corporate Participant Strategic Advisor - Corporate Participant Eric S. Benevich - Chief Commercial Officer Kyle W.
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.98 per share. This compares to earnings of $0.63 per share a year ago.
Achieved Total Net Product Sales of $682 Million Representing 17% Year-Over-Year Growth INGREZZA® (valbenazine) Second-Quarter 2025 Net Product Sales of $624 Million and Narrows 2025 Net Product Sales Guidance to $2.5 - $2.55 Billion CRENESSITY® (crinecerfont) Second-Quarter 2025 Net Product Sales of $53 Million with 664 Total New Patient Enrollment Start Forms SAN DIEGO , July 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance. "As we begin our transition into a new chapter of growth and diversification for Neurocrine, we're pleased with our second quarter commercial performance across tardive dyskinesia, Huntington's chorea, and now, classic congenital adrenal hyperplasia," said Kyle W.
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Neurocrine Biosciences (NBIX). But which of these two companies is the best option for those looking for undervalued stocks?
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Technology-enabled research approach and AI-powered analysis identify unmet needs in patients with congenital adrenal hyperplasia SAN FRANCISCO , July 15, 2025 /PRNewswire/ -- PicnicHealth , a health technology company dedicated to advancing the next generation of non-interventional research, today announced its research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX), the CAHtalog® Registry, identified an unmet need in patients with classic congenital adrenal hyperplasia (CAH). Using PicnicHealth's AI-powered technology to curate medical records and enable remote participation, the study revealed that CAH patients require lifelong, continuous adjustments to glucocorticoid dosing—the current standard treatment—to maintain condition control.